A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Clinical trial NCT04358393 · UNKNOWN

Trial details

NCT number: NCT04358393
Sponsor: Ascentage Pharma Group Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

AML Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia CMML Myelodysplastic Syndromes High-risk Myelodysplastic Syndrome MDS

Start date: 2020-12-04
Primary completion: 2024-12-30
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.